Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?

Group 1 - Humacyte, Inc. (HUMA) has gained approximately 12.4% year-to-date, outperforming the average gain of 7.6% for Medical stocks [4] - The Zacks Rank for Humacyte, Inc. is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The consensus estimate for Humacyte's full-year earnings has increased by 15.9% over the past quarter, reflecting improved analyst sentiment [3] Group 2 - Humacyte, Inc. is part of the Medical - Biomedical and Genetics industry, which has an average gain of 18.6% this year, indicating that HUMA is slightly underperforming its industry [5] - Acrivon Therapeutics, Inc. (ACRV), another Medical stock, has outperformed the sector with a return of 24.9% year-to-date [4] - The Medical - Drugs industry, to which Acrivon belongs, has gained 3.1% this year and is ranked 90 among 141 stocks [6]